

IN THE CLAIMS:

Please cancel Claims 5-8 and 15-17, which are withdrawn from consideration.

Please amend the claims as follows:

Claim 19 (previously amended) A pharmaceutical composition comprising as the active agent, a monoclonal autoantibody comprising a selected from the group consisting of monoclonal autoantibody capable of inducing remyelination of central nervous system axons and synthetic autoantibody capable of inducing remyelination of central nervous system axons.

24. (Amended) A pharmaceutical composition comprising as the active agent, a monoclonal autoantibody comprising selected from the group consisting of an antigen binding fragment of SCH 79.08.